Granules India's Gagillapur facility received EIR from the US FDA

The US FDA has issued an Establishment Inspection Report (EIR) for the Gagillapur facility of the Company located in Hyderabad, Telangana, India.

This facility, that manufacturers finished dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs) was inspected by the US FDA as a part of a PAI in January 2023 which resulted in 3(three) observations during the inspection. The Company responded to these observations within the stipulated period.

Shares of Granules India Limited was last trading in BSE at Rs. 308.70 as compared to the previous close of Rs. 310.15. The total number of shares traded during the day was 151704 in over 3365 trades.

The stock hit an intraday high of Rs. 314.45 and intraday low of 308.20. The net turnover during the day was Rs. 47214701.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 EIR USFDA GagillapurFacility Hyderabad